Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BriaCell Therapeutics Corp. (T:BCT)

Business Focus: Bio Therapeutic Drugs

May 18, 2022 09:15 am ET
BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has activated Hoag Memorial...
Apr 13, 2022 08:00 am ET
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that the U.S. Food and Drug Administration (FDA) has...
Apr 12, 2022 04:30 pm ET
BriaCell Presents Development Details of Bria-OTS™ Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, presented the development details of its novel off-the-shelf...
Apr 07, 2022 08:30 am ET
BriaCell advances preparatory work for new Bria-OTS™ breast cancer clinical trial
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that its novel off-the-shelf (OTS)...
Feb 28, 2022 08:00 am ET
BriaCell Adds Two Clinical Trial Sites to Accelerate Patient Enrollment
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has recruited two additional...
Feb 23, 2022 08:00 am ET
BriaCell Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce that it has appointed...
Feb 16, 2022 08:00 am ET
BriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces the appointment of Giuseppe Del...
Feb 10, 2022 08:00 am ET
BriaCell to Present at the AACR 2022; Provides Corporate Buyback and Insider Buying Update
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, has been selected to present at the American...
Jan 19, 2022 04:57 pm ET
BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), is pleased to announce that all resolutions proposed to shareholders at the Annual and Special Meeting of Shareholders (the “Meeting”) held virtually via...
Jan 11, 2022 08:00 am ET
TMX Group Equity Financing Statistics - December 2021
Toronto Stock Exchange, TSX Venture Exchange
Dec 29, 2021 08:48 pm ET
BriaCell to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under 'BCT'; Remains 'BCTX' on Nasdaq
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to announce that...
Dec 16, 2021 08:00 am ET
BriaCell Announces Insiders’ Intention to Purchase up to 10% of Public Market Securities
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces that certain...
Dec 09, 2021 09:00 am ET
BriaCell Summarizes Clinical Data Poster Presented at the 2021 San Antonio Breast Cancer Symposium®
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, presented clinical results...
Nov 18, 2021 09:00 am ET
BriaCell Adds Mary Crowley Cancer Research Center as a Clinical Trial Site for its Phase I/IIa Breast Cancer Study
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces that Mary Crowley...
Nov 12, 2021 09:00 am ET
BriaCell Announces Update on Previously Announced Securities Buyback Program and Participation at Upcoming Conferences
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announces the following...
Nov 05, 2021 09:00 am ET
BriaCell Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces the addition of...
Nov 02, 2021 09:00 am ET
BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the...
Oct 05, 2021 09:00 am ET
October is Breast Cancer Awareness Month – BriaCell is Advancing the Fight with its Immunotherapy
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, acknowledges that October is Breast Cancer...
Sep 23, 2021 08:00 am ET
BriaCell Therapeutics CEO Emphasizes Recent Key Developments in Audio Interview with SmallCapVoice.com
SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss three key achievements that support the Company’s continued...
Sep 22, 2021 09:00 am ET
BriaCell Announces TSXV Acceptance of Normal Course Issuer Bid
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announces that the TSX Venture Exchange...
Sep 16, 2021 09:00 am ET
BriaCell to Present at the Benzinga Healthcare Small Cap Conference September 29-30
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces today that the Company will be...
Sep 09, 2021 09:00 am ET
BriaCell Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that its board of directors (the...
Sep 01, 2021 09:15 am ET
BriaCell Therapeutics Appoints Marc Lustig to its Board of Directors
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces the appointment of Mr. Marc Lustig...
Aug 23, 2021 08:00 am ET
BriaCell to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces it will be present...
Aug 19, 2021 08:00 am ET
BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, jointly announces a multi-year, non-exclusive...
Jul 14, 2021 07:22 am ET
BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announces the open...
Jul 12, 2021 08:00 am ET
BriaCell to Present at Three Upcoming Investor Conferences
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announced that Dr....
Jun 16, 2021 08:05 am ET
BriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces the advancement of its targeted...
Jun 10, 2021 08:05 am ET
BriaCell Therapeutics Announces Proceeds of US$12.88 Million from Warrant Exercises
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announced today that it has received US$12.88...
Jun 09, 2021 08:05 am ET
BriaCell to Host Corporate and Clinical Update Conference Call Wednesday, June 16, 2021 at 4:30 p.m. ET
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that CEO Dr. William V. Williams will...
Jun 07, 2021 07:50 pm ET
BriaCell Therapeutics Corp. Announces Closing of US$27.2 Million Private Placement
BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW)(TSX-V:BCT) (the "Company" or “BriaCell”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that it has closed its...
Jun 03, 2021 10:31 am ET
IIROC Trading Resumption - BCT
VANCOUVER, BC, June 3, 2021 /CNW/ - Trading resumes in:
Jun 03, 2021 09:41 am ET
BriaCell Therapeutics Corp. Announces US$27.2 Million Private Placement
BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW)(TSX-V:BCT) (the "Company" or “BriaCell”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that it has entered into...
Jun 03, 2021 08:38 am ET
IIROC Trading Halt - BCT
VANCOUVER, BC, June 3, 2021 /CNW/ - The following issues have been halted by IIROC:
Jun 02, 2021 07:12 am ET
BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging’ Tumor
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today provides an update on the overall...
May 19, 2021 05:15 pm ET
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce the results of its annual...
May 11, 2021 06:30 am ET
BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer,   today announced that Dr. William V. Williams,...
Apr 21, 2021 08:00 am ET
BriaCell CEO Gives Corporate Overview, Plans for Future in Audio Interview with SmallCapVoice.com
SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Bill Williams, M.D., President and CEO of BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX-V: BCT) (“the Company”), to discuss the Company’s targeted...
Apr 15, 2021 06:00 pm ET
BriaCell Announces Investor and Media Outreach Programs
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has recently expanded its...
Apr 12, 2021 01:45 pm ET
BriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 Million
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that it has completed the sale...
Apr 12, 2021 06:30 am ET
BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce the presentation of...
Mar 30, 2021 06:30 am ET
BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announces that it has been selected to...
Feb 26, 2021 02:24 pm ET
BriaCell Announces Closing of US$25 Million Public Offering
BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today closed its previously announced...
Feb 23, 2021 11:05 pm ET
BriaCell Announces Pricing of US$25 Million Public Offering and Nasdaq Listing
BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced the pricing of an underwritten...
Jan 26, 2021 06:30 am ET
BriaCell Presents Clinical Data at 2021 Keystone Symposium
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce the presentation of results from...
Jan 12, 2021 06:30 am ET
BriaCell Announces Presentation at the 2021 Keystone Symposia Conference: Emerging Cell Therapies
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce that the Company will present a...
Dec 09, 2020 09:00 am ET
BriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium®
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce the presentation results of the...
Dec 01, 2020 06:30 am ET
BriaCell Appoints Martin Schmieg to Board of Directors
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has...
Nov 17, 2020 04:15 pm ET
BriaCell Therapeutics Corp. Closes Debt Financing
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it has closed a brokered...
Nov 10, 2020 06:30 am ET
BriaCell Announces Collaboration with the National Cancer Institute
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce a Cooperative Research and...
Oct 21, 2020 06:30 am ET
BriaCell Breast Cancer Survival Data: 13.3 Months Versus 7.2-9.8 Months
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces the overall survival (OS) data of its lead...
Oct 06, 2020 06:30 am ET
BriaCell to Present Clinical Findings at the 2020 San Antonio Breast Cancer Symposium®, December 9 – 11
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that its lead product candidate,...
Oct 01, 2020 06:30 am ET
Note from BriaCell Management – October is Breast Cancer Awareness Month
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) is a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer. October is Breast Cancer Awareness Month, an annual...
Sep 15, 2020 06:30 am ET
BriaCell to Present at the 3rd Annual Biologics World Nordic 2020
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing that Dr. Bill Williams, BriaCell’s...
Sep 04, 2020 05:00 pm ET
BriaCell Awarded Research Grant from Wiseman Cancer Research Foundation
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing that it has received a research grant from...
Aug 17, 2020 08:43 pm ET
BriaCell Therapeutics Corp. Announces Completion of Shares for Debt Issuance
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that further to its news release dated August...
Aug 17, 2020 06:30 am ET
BriaCell Presents Clinical and Scientific Findings at the Annual Symposium of Society of Surgical Oncology 2020
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing the results of clinical studies with its...
Aug 11, 2020 02:51 pm ET
Briacell Therapeutics Corp. Announces Shares for Debt Issuance
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has entered into a debt settlement...
Jun 24, 2020 06:30 am ET
BriaCell Files Provisional Patent Application for Novel Treatment and Diagnosis of Coronavirus Disease
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent...
Jun 22, 2020 09:01 am ET
BriaCell Announces Presentation of Clinical and Scientific Findings at AACR Annual Meeting
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing the results of clinical studies with its...
Jun 09, 2020 06:30 am ET
BriaCell CEO to Present at 3rd Annual Next-Gen Immuno-Oncology Congress in June
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Dr. Bill Williams, BriaCell’s...
May 29, 2020 09:00 am ET
BriaCell Presents Clinical Findings at 2020 American Society of Clinical Oncology (ASCO) Meeting
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to present the results of clinical studies...
May 20, 2020 06:30 am ET
BriaCell Files Patent Application for Novel Immune Therapies for Multiple Disease Indications
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent...
May 14, 2020 06:30 am ET
BriaCell Announces Presentation and Abstract Publication at 2020 American Society of Clinical Oncology (ASCO) Meeting
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces the publication of its abstract in the ASCO...
May 12, 2020 06:30 am ET
BriaCell Continues Business and Clinical Operations During COVID-19 Pandemic
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that the Phase I/IIa clinical study of...
Apr 27, 2020 06:30 am ET
BriaCell Files Patent Application for Novel Therapeutics for Cancer
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent...
Apr 21, 2020 06:30 am ET
BriaCell Files New Provisional Patent Application for Antibody-Based Treatment of Infectious Diseases
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent...
Apr 14, 2020 06:30 am ET
BriaCell Files Coronavirus Immunotherapy Patent
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent...
Mar 31, 2020 06:30 am ET
BriaCell to Present Clinical Data at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting May 29
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has been selected to present at the...
Mar 26, 2020 06:30 am ET
BriaCell Continues Clinical Operations Amidst COVID-19 Pandemic
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announce that the Phase I/IIa clinical study of Bria-IMT™...
Feb 26, 2020 06:30 am ET
BriaCell to Present Clinical and Immune Activity at AACR Annual Meeting
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it has been selected to...
Feb 21, 2020 09:42 am ET
BriaCell Announces Proposed Public Offering in the United States and Listing on NASDAQ
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it has commenced an...
Feb 11, 2020 06:30 am ET
BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health for Phase I/IIa Combination Study of Bria-IMT™
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that Dr. Saveri Bhattacharya, a...
Jan 28, 2020 06:30 am ET
BriaCell’s Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce that the data of its clinical...
Jan 22, 2020 06:30 am ET
BriaCell Invited to Present at Mount Sinai’s Frontiers in Academic Pathology Symposium at The New York Academy of Medicine
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announced today that it will present at the “Frontiers...
Jan 13, 2020 06:30 am ET
BriaCell Provides Update on Remarkable Responder
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to provide an update on the...
Jan 09, 2020 06:30 am ET
BriaCell Outlines New High Responding Patient Group ‘Biomarker’ Based on Cancer Grade
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce it has identified a new group of...
Jan 02, 2020 04:48 pm ET
BriaCell Completes Share Consolidation
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it has completed its...
Dec 24, 2019 06:30 am ET
BriaCell Therapeutics Corp. Announces Share Consolidation
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that its Board of Directors has approved a...
Dec 17, 2019 06:30 am ET
BriaCell to Present at Biotech Showcase™ 2020 in San Francisco
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces its attendance and presentation scheduled at...
Dec 13, 2019 06:30 am ET
BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium®
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce the presentation results of...
Nov 12, 2019 06:30 am ET
BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce its lead product candidate,...
Oct 24, 2019 06:30 am ET
BriaCell Announces Voting Results of the Special Meeting of Shareholders
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that the shareholders approved all...
Oct 15, 2019 05:33 pm ET
BriaCell Announces Closing of Non-Brokered Private Placement of $568,444
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has closed its previously-announced...
Oct 08, 2019 07:00 pm ET
BriaCell Therapeutics Corp. to File Amendment to Management Information Circular
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed on SEDAR an amendment to its...
Oct 07, 2019 06:30 am ET
BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that it has initiated dosing in a Phase...
Oct 01, 2019 07:00 pm ET
BriaCell Therapeutics Corp. to Clarify Record Date
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announced on August 23, 2019 that it will hold a special...
Oct 01, 2019 06:30 am ET
Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) is a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer.  October is Breast Cancer Awareness Month, an annual...
Sep 25, 2019 06:30 am ET
BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy’ Issue in Prestigious Journals
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced the addition of immunology expert, Cara...
Sep 20, 2019 11:03 am ET
BriaCell Announces Private Placement of up to $600,000
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce a non-brokered private placement...
Sep 19, 2019 11:29 am ET
IIROC Trading Resumption - BCT
VANCOUVER, Sept. 19, 2019 /CNW/ - Trading resumes in:
Sep 19, 2019 10:00 am ET
BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announces that Dr. Williams, BriaCell’s President &...
Sep 19, 2019 09:12 am ET
IIROC Trading Halt - BCT
VANCOUVER, Sept. 19, 2019 /CNW/ - The following issues have been halted by IIROC:
Sep 16, 2019 06:30 am ET
BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announces that the Company will be presenting at...
Sep 10, 2019 08:55 am ET
Bondarenko Acquires 16.2% Beneficial Ownership of BriaCell Therapeutics Corp.
Jamieson Bondarenko (“Bondarenko”) announced today that he has acquired an aggregate of 3,154,302 common shares (the “Shares”) of BriaCell Therapeutics Corp. (BCT-TSXV) (“BriaCell”). Bondarenko acquired the Shares through BriaCell’s...
Sep 09, 2019 05:33 pm ET
BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has upsized and closed its...
Aug 27, 2019 06:30 am ET
BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced it will be featured as a presenting...
Aug 12, 2019 06:30 am ET
BriaCell Appoints Richard J. Berman to Board of Directors
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that it has appointed Mr. Richard J....
Jul 23, 2019 06:30 am ET
BriaCell Announces $350,000 Equity Investment by Board of Directors
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it intends to complete a...
May 28, 2019 06:30 am ET
BriaCell’s Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that BriaCell’s clinical findings were...
May 17, 2019 09:24 am ET
Bondarenko Acquires 14.48% Beneficial Ownership of BriaCell Therapeutics Corp.
Jamieson Bondarenko (“Bondarenko”) announced today that he has acquired an aggregate of 1,698,000 common shares (the “Shares”) of BriaCell Therapeutics Corp. (BCT-TSXV) (“BriaCell”). Bondarenko acquired the Shares through the facilities of the TSX...
May 13, 2019 06:30 am ET
BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that the shareholders approved all...
Apr 23, 2019 06:30 am ET
BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that BriaCell’s clinical findings will be...
Apr 03, 2019 08:30 am ET
BriaCell's Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced early efficacy data of BriaCell’s novel...
Apr 02, 2019 03:15 pm ET
IIROC Trading Resumption - BCT
VANCOUVER, April 2, 2019 /CNW/ - Trading resumes in:
Apr 02, 2019 02:58 pm ET
BriaCell Announces Clinical Trial Collaboration Agreement with Incyte
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced a clinical trial collaboration and supply...
Apr 02, 2019 02:34 pm ET
IIROC Trading Halt - BCT
VANCOUVER, April 2, 2019 /CNW/ - The following issues have been halted by IIROC:
Apr 01, 2019 06:45 pm ET
BriaCell Announces Closing of Upsized & Oversubscribed Non-Brokered Private Placement of $2.97 Million
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has upsized and closed the second and...
Mar 26, 2019 06:30 am ET
BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce it is finalizing the analysis of...
Mar 25, 2019 09:26 pm ET
Jamieson Bondarenko Acquires 5,000,000 Common Shares of BriaCell Therapeutics Corp.
Jamieson Bondarenko (“Bondarenko”) announced today that he has acquired an aggregate of 5,000,000 common shares (the “Shares”) of BriaCell Therapeutics Corp. (BCT-TSXV) (“BriaCell”). Bondarenko acquired the Shares through BriaCell’s...
Mar 25, 2019 04:05 pm ET
BriaCell Closes First Tranche of Previously Announced Non-Brokered Private Placement
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it has closed the first...
Mar 20, 2019 04:05 pm ET
BriaCell Announces $2,000,000 Non-Brokered Private Placement Offering
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it intends to complete a...
Mar 18, 2019 06:30 am ET
BriaCell Welcomes BioPharma Industry Experts to its Board of Directors
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announces changes to its Board of Directors....
Mar 07, 2019 06:30 am ET
BriaCell Therapeutics Corp. Highlights Recent Clinical and Scientific Achievements in Exclusive Audio Interview with NetworkNewsWire
via NetworkWire - NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview...
Feb 26, 2019 06:30 am ET
BriaCell Announces C$500,000 Equity Investment by BriaCell Director
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce a non-brokered private placement...
Feb 19, 2019 06:30 am ET
BriaCell to Present Clinical and Scientific Findings with New Insights at Key Oncology Conferences
BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) ("BriaCell" or the "Company"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, today announces it has been selected to present a poster at...
Feb 12, 2019 07:57 pm ET
Jamieson Bondarenko Acquires 11.0% Beneficial Ownership of BriaCell Therapeutics Corp.
Jamieson Bondarenko (“Bondarenko”) announced today that he has acquired an aggregate of 2,000,000 common shares (the “Shares”) of BriaCell Therapeutics Corp. (BCT-TSXV) (“BriaCell”). Bondarenko acquired the Shares through the facilities of the TSX...
Feb 12, 2019 06:30 am ET
BriaCell Appoints Jamieson Bondarenko to its Board of Directors
BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) ("BriaCell" or the "Company"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, today announces the appointment of Jamieson Bondarenko to...
Jan 02, 2019 06:30 am ET
BriaCell Announces Switch to Novel Frozen Formulation for Lead Cancer Drug Candidate, Upcoming Attendance at Biotech Showcase™ 2019 and Presentation at Keystone Symposia Conference
BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) ("BriaCell" or the "Company"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, today announces the imminent clinical use of a new novel,...
Dec 06, 2018 08:30 am ET
BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announces the presentation of initial safety data in the...
Nov 20, 2018 06:54 pm ET
UPDATE - BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposi
BriaCell Therapeutics Corp. (“BriaCell,” the “Company”) (TSX-V: BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that Bria-IMT™ will be featured in a...
Nov 19, 2018 06:30 am ET
BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium
BriaCell Therapeutics Corp. (“BriaCell,” the “Company”) (TSX-V: BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that Bria-IMT™ will be featured in a...
Oct 09, 2018 06:30 am ET
BriaCell Initiates Dosing in Phase I/IIa Combination Study with KEYTRUDA® or YERVOY®
BriaCell Therapeutics Corp. (“BriaCell”, the “Company”) (TSX-V: BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that it has initiated patient dosing...
Oct 04, 2018 09:00 am ET
NetworkNewsAudio Announces Audio Press Release (APR) on BriaCell Therapeutics Corp. Leveraging Combination Studies, Immune Checkpoint Inhibitors for Potent Anti-Cancer Response
New York, New York--(Newsfile Corp. - October 4, 2018) - NetworkNewsAudio announces the Audio Press Release (APR) titled "Personalized Immunotherapy Could Be the Future for Advanced Breast Cancer Treatment," featuring BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSXV: BCT).
Oct 04, 2018 08:30 am ET
NetworkNewsAudio Announces Audio Press Release (APR) on BriaCell Therapeutics Corp. Achieving Superior Responses in Breast Cancer Immunotherapy Trials
via NetworkWire – NetworkNewsAudio announces the Audio Press Release (APR) titled “Personalized Immunotherapy Could Be the Future for Advanced Breast Cancer Treatment,” featuring BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT). To hear the...
Oct 03, 2018 08:30 am ET
NetworkNewsWire Announces Publication on Hope on the Horizon with Innovative Breast Cancer Therapies
via NetworkWire — NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), a client of NNW focused on developing...
Sep 26, 2018 04:13 pm ET
IIROC Trading Resumption - RTB.P; FCO; BCT; KAPA.P
VANCOUVER, Sept. 26, 2018 /CNW/ - Trading resumes in:
Sep 26, 2018 04:11 pm ET
IIROC Trade Resumption - BriaCell Therapeutics Corp.
Vancouver, British Columbia--(Newsfile Corp. - September 26, 2018) - Trading resumes in:
Sep 26, 2018 02:30 pm ET
BriaCell Announces Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer; Initiates Combination Study
BriaCell Therapeutics Corp. (“BriaCell”, the “Company”) (TSX-V: BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that it has achieved proof of concept...
Sep 26, 2018 02:08 pm ET
IIROC Trade Halt - BriaCell Therapeutics Corp.
Vancouver, British Columbia--(Newsfile Corp. - September 26, 2018) - The following issues have been halted by IIROC:
Sep 26, 2018 02:04 pm ET
IIROC Trading Halt - BCT
VANCOUVER, Sept. 26, 2018 /CNW/ - The following issues have been halted by IIROC:
Sep 25, 2018 06:30 am ET
BriaCell Therapeutics Corp. Discusses its Plan to Revolutionize Cancer Immunotherapy in Exclusive NetworkNewsWire Audio Interview
via NetworkWire - NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with...
Sep 21, 2018 08:30 am ET
Coverage Initiated for BriaCell Therapeutics Corp. via NetworkNewsWire
via NetworkWire – BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V) (BriaCell or the Company), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announces that it has selected...
Sep 21, 2018 06:30 am ET
BriaCell to Present Clinical and Scientific Data at International Cancer Immunotherapy and The MicroCap Conferences
Scientific findings will discuss circulating tumor cells as a biomarker of tumor response, which is key to the advancement of BriaCell's BriaDX™, a diagnostic test designed to determine which patients are most likely to respond to treatment.
Aug 28, 2018 08:00 am ET
Dr. William Williams, BriaCell’s President & CEO, is Featured in an Exclusive New Audio Interview at SmallCapVoice.com
SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. ("BriaCell") (BCT.V) (BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s President CEO, Dr....
Aug 08, 2018 06:30 am ET
BriaCell Adds New Clinical Site To Phase IIa Study in Advanced Breast Cancer and Expands R&D Team
BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that the Cancer Center of Kansas (CCK) has been added...
Jun 21, 2018 10:09 am ET
BriaCell to Hold Conference Call on Key Clinical Findings; Activities
BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to provide a Corporate Update on its activities and new...
Jun 13, 2018 12:45 pm ET
BriaCell Therapeutics Corp. to Present at The MicroCap Conference on June 21st in Toronto at the Sheraton Centre Hotel
TORONTO, ON / ACCESSWIRE / June 13, 2018 / BriaCell Therapeutics Corp. ("BriaCell") (TSX-V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, will be presenting at this year's MicroCap Conference on June 21st in Toronto, Canada. Dr. Bill Williams, BriaCell's President and CEO will discuss Bria-IMT™, BriaCell's lead clinical candidate, its potential in treating breast cancer, and its advantages over similar immuno-oncology therapeutics. He will also discuss the clinical development plans
Jun 13, 2018 08:00 am ET
Dr. Williams, BriaCell Therapeutics Corp.’s President & CEO, Discusses Recent News and Progress in an Exclusive New Audio Interview with SmallCapVoice.com
SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT.V) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s President ...
May 29, 2018 06:30 am ET
BriaCell Publishes Clinical Findings in 2018 American Society of Clinical Oncology (ASCO) Meeting
BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it will publish its clinical findings in the American...
May 21, 2018 06:30 am ET
BriaCell’s Lead Product Candidate’s Novel Mechanism of Action Published in a Reputable Immunology Journal
BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the publication of  the novel mechanism of action of...
Apr 26, 2018 06:15 pm ET
Sagittarius Capital Announces Closing of Oversubscribed IRRI-Al-Tal Private Placement and Amendment to the LOI
TORONTO, April 26, 2018 (GLOBE NEWSWIRE) -- Sagittarius Capital Corporation (NEX Board:SCX.H) ("Sagittarius" or the "Company"), a capital pool company, is pleased to announce the first closing of IRRI-Al-Tal Ltd.’s ("IRRI-Al-Tal") previously announced brokered private placement of units...
Apr 23, 2018 06:30 am ET
BriaCell Activates A Clinical Site in Florida for Phase IIa Study of its Lead Candidate in Advanced Breast Cancer
BERKELEY, Calif. and VANCOUVER, British Columbia, April 23, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that Sylvester Comprehensive Cancer Center...
Apr 18, 2018 09:30 am ET
BriaCell Provides Highlights of Scientific and Clinical Findings at AACR
- Early data points to safety and early efficacy of Bria-IMT™ in Advanced Stage IV Breast cancer -
Apr 11, 2018 08:00 am ET
Dr. Williams, BriaCell Therapeutics Corp.’s President & CEO, is Featured in an Exclusive New Audio Interview with SmallCapVoice.com
AUSTIN, Texas, April 11, 2018 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. ("BriaCell") (TSXV:BCT.V) (OTC:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s President & CEO, Dr. Williams,...
Apr 10, 2018 08:30 am ET
BriaCell to Present Encouraging Clinical Data at AACR 2018
- Early Evidence of Safety and Impressive Anti-Tumor Activity of Bria-IMT™ -
Apr 03, 2018 08:30 am ET
BriaCell’s Lead Product Candidate Mechanism of Action Described in a Major Immunology Journal
BERKELEY, Calif. and VANCOUVER, British Columbia, April 03, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the acceptance of a manuscript...
Mar 27, 2018 08:30 am ET
Mar 14, 2018 12:21 pm ET
BriaCell Appoints Top Social Media Marketing Analyst
BERKELEY, Calif. and VANCOUVER, British Columbia, March 14, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it has engaged Akari Health, a leading...
Mar 07, 2018 07:59 pm ET
Mar 01, 2018 08:30 am ET
BriaCell To Present at Precision Breast Cancer Conference
BERKELEY, Calif. and VANCOUVER, British Columbia, March 01, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that Dr. Bill Williams, BriaCell’s President & CEO,...
Feb 07, 2018 08:30 am ET
BriaCell to Attend 20th Annual BIO CEO & Investor Conference
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 07, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it will be attending BIO CEO &...
Feb 06, 2018 08:30 am ET
BriaCell Opens Fourth Clinical Site in Advanced Breast Cancer
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 06, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the opening of a new...
Feb 05, 2018 08:30 am ET
BriaCell Presenting at Upcoming Cancer Conference
Further Investigation on Mechanism of Action of its Lead Drug Candidate, Bria-IMT™, at AACR event
Jan 31, 2018 08:30 am ET
BriaCell Update:  Early Evidence of Efficacy and Safety of Bria-IMT™
BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 31, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, provides an update on its operations.
Jan 03, 2018 12:56 pm ET
BriaCell Provides Clinical Update on its Lead Immunotherapy Drug in Advanced Breast Cancer
BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 03, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is providing a clinical update regarding its ongoing clinical...
Jan 02, 2018 08:30 am ET
BriaCell To Attend Biotech Showcase™ 2018
BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 02, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it will be attending Biotech Showcase™ 2018....
Dec 21, 2017 02:58 pm ET
BriaCell Announces Closing of Warrant Incentive Program
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRE SERVICES
Dec 05, 2017 03:41 pm ET
Dr. Bill Williams Guest Appearance at “CEO MONEY” Radio Show
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 05, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that Dr. Bill Williams,...
Nov 13, 2017 08:30 am ET
BriaCell Announces Advancement of its Small Molecule Program and Patent Allowance
BERKELEY, Calif. and VANCOUVER, British Columbia, Nov. 13, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today disclosed the allowance by the US...
Nov 06, 2017 08:30 am ET
BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax™
BERKELEY, Calif. and VANCOUVER, British Columbia, Nov. 06, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today released a clinical update on its...
Oct 03, 2017 05:54 pm ET
BriaCell Announces Repricing of Warrants
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRE SERVICES...
Aug 02, 2017 08:30 am ET
BriaCell Announces Additional Capital Support by the CEO
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce that Dr. William Williams, BriaCell's...
Jul 31, 2017 08:30 am ET
BriaCell Appoints Top Oncologist and Opens Second Clinical Site for its Ongoing Clinical Trial in Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce the opening of a new clinical site, Florida...
Jul 24, 2017 08:30 am ET
BriaCell Expands Targeted Pipeline via Acquisition of Sapientia Pharmaceuticals
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce that it has entered into a definitive share...
Jul 19, 2017 08:30 am ET
BriaCell Provides Clinical Update on its Ongoing Phase I/IIa Clinical Study of BriaVax(TM) in Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, provided a clinical update regarding its US-based open-label Phase I/IIa clinical trial evaluating the...
Jul 05, 2017 08:30 am ET
BriaCell Completes Manufacturing of New Batch of BriaVax(TM)
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, announced today that it has successfully manufactured a new batch of its BriaVax™ vaccine, and that this...
Jun 01, 2017 08:30 am ET
BriaCell Doses Second Patient in Phase I/IIa Clinical Study of BriaVax(TM) in Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company announced today it has enrolled the second patient in a USA-based open-label Phase I/IIa clinical trial...
May 31, 2017 08:30 am ET
BriaCell Launches Its Scientific Advisory Board
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), announced today the establishment of its Scientific Advisory Board (SAB) engaging a number of highly-experienced leading experts in the field of...
May 08, 2017 08:30 am ET
BriaCell Announces First Patient Dosed in Phase I/IIa Clinical Study of BriaVax(TM) in Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, today announced dosing of the first patient in BriaCell's Phase I/IIa clinical trial evaluating the...
Mar 24, 2017 06:22 pm ET
BriaCell Closes CEO Equity Investment
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the "Offering") of 5,612,083 units (the "Units")...
Mar 15, 2017 08:30 am ET
BriaCell Receives FDA Clearance to Initiate Phase I/IIa Clinical Trial of BriaVax(TM) in Patients with Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today announced that the U.S. Food and Drug Administration (FDA) has...
Mar 07, 2017 08:30 am ET
BriaCell Files New Patent Application for its Whole-Cell Breast Cancer Vaccine and Companion Diagnostic Platforms
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) today announced that it has filed an international patent application under the Patent Cooperation Treaty (PCT) to further expand its intellectual property...
Feb 27, 2017 08:30 am ET
BriaCell CEO Equity Investment Advances Company's Lead Cancer Product and Pipeline Expansion
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) announced today that its President and CEO, Dr. William Williams has entered into a non-brokered private placement (the "Offering") of 5,416,667 units of the...
Feb 06, 2017 08:30 am ET
BriaCell Moves Forward to Initiate Phase I/IIa Clinical Study for BriaVax(TM) in Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage company dedicated to the development of immuno-oncology treatments, today announced that the Company has submitted a Chemistry,...
Jan 05, 2017 11:08 am ET
BriaCell Included in the List of Key Players in Immuno-Oncology
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of novel immuno-oncology therapeutics, today announced that Jason Napodano, senior...
Dec 05, 2016 08:30 am ET
BriaCell to Present at a Breast Cancer Symposium, and Enters into a Research Agreement with Terasaki Foundation Laboratory
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage company dedicated to the development of immuno-oncology treatments, today announced that the Company will present the latest development...
Nov 29, 2016 08:30 am ET
BriaCell Files a Patent Application for its Companion Diagnostic Platform to complement BriaVax(TM)
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of immuno-oncology treatments, is pleased to announce that it has filed a patent...
Nov 10, 2016 02:37 pm ET
BriaCell Provides Clinical Development Update on BriaVax(TM)
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of immuno-oncology treatments that can enhance the lives of cancer patients, today...
Oct 26, 2016 11:27 am ET
BriaCell Announces the Appointment of Biotechnology Veteran William Williams as New CEO and Director
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of immuno-oncology treatments that can enhance the lives of cancer patients, is...
Sep 27, 2016 08:30 am ET
BioNap Consulting's Jason Napodano Issues an Update on BriaCell Therapeutics Corp.
BioNap Consulting, Inc.'s Senior Equity Analyst, Jason Napodano, CFA, issued an update outlining the meaningful progress of BriaCell Therapeutics Corp. (TSX VENTURE: BCT) (OTCQB: BCTXF) or BriaCell towards initiation of Phase I/IIa clinical testing...
Sep 15, 2016 08:30 am ET
BriaCell Appoints New York-Based RK Equity Advisors and TrueNorth Lifesciences as Corporate Advisor
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that it has entered into an agreement (the "Agreement") with RK Equity Advisors LLC and TrueNorth Lifesciences LLC ("RK TrueNorth")...
Aug 19, 2016 04:01 pm ET
BriaCell Closes Oversubscribed Non-Brokered Private Placement
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE:BCT)(OTCQB:BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the "Offering") of units (the "Units") for aggregate...
Aug 19, 2016 04:01 pm ET
BriaCell Closes Oversubscribed Non-Brokered Private Placement
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT)(OTCQB: BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the "Offering") of units (the "Units") for aggregate gross proceeds to the Company in the amount of $1,700,000.
Aug 17, 2016 08:30 am ET
BriaCell Appoints the Lead Principal Investigator and First Clinical Site for Its Upcoming Phase I/IIa Clinical Trial in Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that Dr. Jarrod P. Holmes, a Board Certified Oncologist and a leading expert in breast cancer vaccines at Annadel Medical Group and...
Aug 12, 2016 08:37 am ET
BriaCell Announces Non-Brokered Private Placement
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRE SERVICES BriaCell Therapeutics Corp. (OTCQB:BCTXF)(TSX VENTURE:BCT) ("BriaCell", the "Company", or "BCT") announced today that it intends to complete a...
May 18, 2016 08:30 am ET
BriaCell Appoints Contract Research Organization, Cancer Insight, to Manage Its Upcoming Phase I/IIa Clinical Trials in Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that it has signed a definitive agreement with Cancer Insight, LLC, a cancer-vaccine focused clinical research organization (CRO), to...
May 10, 2016 08:30 am ET
BriaCell Adds U.S. Biotech Veteran to Its Board of Directors
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT)(OTCQB: BCTXF) today announced a change to its board of directors.BriaCell is pleased to welcome the appointment of Mr. Martin Schmieg to its Board of Directors. Mr....
May 03, 2016 08:30 am ET
BriaCell Completes Previously Announced Investment With Leading U.S. Biotech Fund and Non-Brokered Private Placement
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that the Company has completed both its previously announced brokered and non-brokered private placements of units totaling gross...
Apr 22, 2016 03:06 pm ET
BriaCell Announces Non-Brokered Private Placement
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRE SERVICES BriaCell Therapeutics Corp. (TSX VENTURE:BCT)(OTCQB:BCTXF) ("BriaCell", the "Company", or "BCT") announced today that it intends to complete a non-brokered private...
Apr 22, 2016 09:03 am ET
BriaCell Announces Proposed Investment by Leading US Biotech Fund
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRE SERVICES BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE:BCT)(OTCQB:BCTXF) announced today that it has entered into a subscription agreement with a...
Apr 12, 2016 08:30 am ET
BriaCell Files a Patent Application to Protect Additional Cancer Vaccines With Genetic Features Thought to Promote Strong Anti-Tumor Activity
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is very pleased to announce that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) outlining certain features...
Apr 05, 2016 09:33 am ET
BriaCell Targeting Launch of Its Phase I/II Clinical Trial During Current Quarter
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is very pleased to provide an update in regard to the planned timing of its Phase I/II clinical trial for up to 24 late-stage cancer patients. BriaCell has...
Mar 29, 2016 09:30 am ET
BriaCell Discovers Gene Signature of BriaVax(TM) Cancer Vaccine Consistent With Exceptional Efficacy in Clinical Trial
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is very pleased to announce that it has discovered a gene signature potentially explaining why its BriaVax™ cancer vaccine was exceptionally efficacious in...
Mar 24, 2016 05:30 pm ET
BriaCell Announces Senior Management Change
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX VENTURE: BCT) (the "Company") announces that Dr. Joseph Wagner has resigned his positions as President and Chief Executive Officer of the Company, effective immediately, in order to pursue other opportunities. Dr. Wagner has also stepped down from the Board. Mr. Rahoul Sharan, Director of the Company, has been appointed Chief Executive Officer on an interim basis as the Board searches for a suitable long-term replacement. Mr. Sharan brings 25 years of corporate finance experience where he has led financings in excess of several